Rize Oncology Inc.
RIZE
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -7.42% | 316.77% | -22.58% | -25.08% | -19.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -47.52% | 212.27% | -23.58% | -24.85% | -11.39% |
| Operating Income | 47.52% | -212.27% | 23.58% | 24.85% | 11.39% |
| Income Before Tax | 46.17% | -366.30% | 23.11% | 29.42% | 16.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 46.17% | -366.30% | 23.11% | 29.42% | 16.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.17% | -366.30% | 23.11% | 29.42% | 16.24% |
| EBIT | 47.52% | -212.27% | 23.58% | 24.85% | 11.39% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 45.68% | -450.00% | 3.45% | 11.90% | 40.88% |
| Normalized Basic EPS | 46.00% | -425.00% | 5.56% | 11.54% | 41.18% |
| EPS Diluted | 45.68% | -450.00% | 3.45% | 11.90% | 40.88% |
| Normalized Diluted EPS | 46.00% | -425.00% | 5.56% | 11.54% | 41.18% |
| Average Basic Shares Outstanding | -1.26% | -20.72% | -20.13% | -19.96% | 41.92% |
| Average Diluted Shares Outstanding | -1.26% | -20.72% | -20.13% | -19.96% | 41.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |